Acute Ischemic Apoplexy Syndrome Specificity and Acupuncture Intervention Research
Acute Ischemic Apoplexy Syndrome Specificity and Acupuncture Intervention Research
This project optimizes the TCM Symptoms and Symptoms Scale. A curative effect evaluation
 system of acupuncture in the treatment of acute ischemic stroke is formed to provide clinical
 evidence by the following indexes: neurological impairment, motor dysfunction, TCM Symptoms
 and Symptoms Scale, combined with the patients' head MRI, Plasma BDNF, MMP-9 and other
 biomarkers.
Based on the previous work, this project optimizes the TCM Symptoms and Symptoms Scale.
 Through the cohort study method, 194 patients with acute ischemic stroke were evaluated for
 neurological impairment, motor dysfunction, TCM Symptoms and Symptoms Scale, combined with
 the patients' head MRI. , Plasma BDNF, MMP-9 and other biomarkers, screen TCM syndromes
 related to stroke outcome indicators, and adopt targeted comprehensive acupuncture and
 moxibustion program intervention and follow-up to establish a stroke-specific intervention
 outcome prediction model with TCM characteristics. A curative effect evaluation system of
 acupuncture and moxibustion in the treatment of acute ischemic stroke is formed to provide
 clinical evidence.
Inclusion Criteria:

 -  (1) It meets the diagnostic criteria in the "Chinese Guidelines for the Diagnosis and
 Treatment of Acute Ischemic Stroke 2014"; with the support of brain CT or MRI imaging
 examination, the vital signs are stable, the state of consciousness is clear, and the
 GCS>8 points; （2）.Onset is less than 2 weeks; （3）. There is no indication for
 thrombolysis, or the patient do not accept thrombolysis; （4）. For moderate to severe
 patients, the National Institute of Health Stroke Scale (NIHSS) ≥ 4 points;（5）.Glasgow
 coma standard (GCS)>7 points;（6）.No serious disability before admission, and modified
 Rankin Scale (mRS) ≤ 3;（7）. The patient himself or his immediate family members signed
 the informed consent form.

 Exclusion Criteria:

 - (1) Cerebral hemorrhage or subarachnoid hemorrhage; (2) Cerebellar and brainstem
 infarction (including lacunar infarction); (3) Cerebral herniation is formed upon
 admission; (4) Patients with severe heart, lung, liver, and kidney diseases; (5) Severe
 upper gastrointestinal bleeding occurred after the onset; (6) The patient has participated
 in other clinical trials within the past 3 months; (7) Patients with mental illness, or
 those with severe cognitive impairment (MMSE score ≤9 points) (8) Those with a pacemaker, a
 metal foreign body at the treatment site, or a severe bleeding tendency.

 (9) The investigator believes that other diseases accompanied by the patient may interfere
 with the correct evaluation of neurological function, or participating in this trial may
 cause other complications in the patient.